J Korean Soc Radiol.  2019 Sep;80(5):860-871. 10.3348/jksr.2019.80.5.860.

Risk Prediction Model for Lung Cancer Screening

• Kim TJ
• Kim HY
• Goo JM
• Sun JS

• KMID: 2459012
• DOI: http://doi.org/10.3348/jksr.2019.80.5.860

Abstract

Lung cancer screening in high-risk subjects using low-dose CT can reduce mortality by 20%. Current evidence suggests that the development of a risk prediction model for lung cancer is one of the major advances in lung cancer screening. Herein, we review the technical requirements for evaluating different risk prediction models. Moreover, we describe the major lung cancer risk prediction models reported, and the results of lung cancer screening using these models.

MeSH Terms

Lung Neoplasms*
Lung*
Mass Screening*
Mortality
Risk Assessment
Tomography, X-Ray Computed

Reference

1. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395–409.

2. Moyer VA. U.S. Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160:330–338.

3. Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, et al. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012; 144:25–32.

4. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63:107–117.

5. Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, et al. Lung cancer screening. J Natl Compr Canc Netw. 2012; 10:240–265.

6. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307:2418–2429.

7. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999; 130:515–524.

8. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009; 338:b605.

9. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003; 56:826–832.

10. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000; 19:453–473.

11. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. Hoboken: John Wiley & Sons;2013.

12. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012; 98:691–698.

13. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009; 338:b604.

14. Sakoda LC, Henderson LM, Caverly TJ, Wernli KJ, Katki HA. Applying risk prediction models to optimize lung cancer screening: current knowledge, challenges, and future directions. Curr Epidemiol Rep. 2017; 4:307–320.

15. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003; 95:470–478.

16. Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J, Albanes D. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst. 2006; 98:637–640.

17. Cassidy A, Myles JP, Van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008; 98:270–276.

18. Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a casecontrol and cohort validation study. Ann Intern Med. 2012; 157:242–250.

19. D'Amelio AM Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer. 2010; 103:423–429.

20. McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014; 7:362–337.

21. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007; 99:715–726.

22. Etzel CJ, Kachroo S, Liu M, D'Amelio A, Dong Q, Cote ML, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila). 2008; 1:255–265.

23. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst. 2011; 103:1058–1068.

24. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lungcancer screening. N Engl J Med. 2013; 368:728–736.

25. Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014; 11:e1001764.

26. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Østergaard JN, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila). 2012; 5:834–846.

27. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2008; 1:250–254.

28. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, et al. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J. 2009; 85:515–524.

29. Park S, Nam BH, Yang HR, Lee JA, Lim H, Han JT, et al. Individualized risk prediction model for lung cancer in Korean men. PLoS One. 2013; 8:e54823.

30. Tammemagi MC, Lam SC, McWilliams AM, Sin DD. Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res (Phila). 2011; 4:552–561.

31. Li H, Yang L, Zhao X, Wang J, Qian J, Chen H, et al. Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model. BMC Med Genet. 2012; 13:118.

32. Hippisley-Cox J, Coupland C. Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011; 61:e715–e723.

33. Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJ, Hubbard RB. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax. 2013; 68:451–459.

34. U.S. National Library of Medicine. International lung screen trial (ILST). Apr 6, 2019. Available at. https://clinicaltrials.gov/ct2/show/NCT02871856.

35. Cancer Center Ontario. Apr 6, 2019. Available at. https://www.cancercareontario.ca/en/types-of-cancer/lung.

36. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013; 369:910–919.

37. White CS, Dharaiya E, Campbell E, Boroczky L. The Vancouver lung cancer risk prediction model: assessment by using a subset of the national lung screening trial cohort. Radiology. 2017; 283:264–272.

38. White CS, Dharaiya E, Dalal S, Chen R, Haramati LB. Vancouver risk calculator compared with ACR lung-RADS in predicting malignancy: analysis of the national lung screening trial. Radiology. 2019; 291:205–211.

39. Kim H, Park CM, Jeon S, Lee JH, Ahn SY, Yoo RE, et al. Validation of prediction models for risk stratification of incidentally detected pulmonary subsolid nodules: a retrospective cohort study in a Korean tertiary medical centre. BMJ Open. 2018; 8:e019996.

40. Kim H, Goo JM, Park CM. A simple prediction model using size measures for discrimination of invasive adenocarcinomas among incidental pulmonary subsolid nodules considered for resection. Eur Radiol. 2019; 29:1674–1683.

41. Jung KJ, Jeon C, Jee SH. The effect of smoking on lung cancer: ethnic differences and the smoking paradox. Epidemiol Health. 2016; 38:e2016060.

42. Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget. 2015; 6:5465–5474.